{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T07:45:15Z","timestamp":1787816715045,"version":"build-2784847793"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82374391"],"award-info":[{"award-number":["82374391"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2023A1515011127"],"award-info":[{"award-number":["2023A1515011127"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Project in Key Fields of universities in Guangdong Province","award":["2021ZDZX2032"],"award-info":[{"award-number":["2021ZDZX2032"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12035-025-05523-y","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T07:42:49Z","timestamp":1770277369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Global Research Landscape in T Cells and Myasthenia Gravis: Trends, Collaborations, and Future Directions"],"prefix":"10.1007","volume":"63","author":[{"given":"Yingying","family":"Jiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zien","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwen","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoqi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"5523_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/B978-0-323-90820-7.00006-9","volume":"203","author":"M Pasnoor","year":"2024","unstructured":"Pasnoor M, Wolfe GI, Barohn RJ (2024) Myasthenia gravis. Handb Clin Neurol 203:185\u2013203","journal-title":"Handb Clin Neurol"},{"key":"5523_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120268","volume":"437","author":"D Gelinas","year":"2022","unstructured":"Gelinas D, Parvin-Nejad S, Phillips G et al (2022) The humanistic burden of myasthenia gravis: a systematic literature review. J Neurol Sci 437:120268","journal-title":"J Neurol Sci"},{"key":"5523_CR3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/bs.irn.2025.04.024","volume":"182","author":"ML Fichtner","year":"2025","unstructured":"Fichtner ML, Horstkorte L, S\u00e1nchez Navarro BG, Schmidt H, Cabraal I, Waters PJ, Leite MI (2025) Autoantibodies in myasthenia gravis. Int Rev Neurobiol 182:89\u2013119. https:\/\/doi.org\/10.1016\/bs.irn.2025.04.024","journal-title":"Int Rev Neurobiol"},{"issue":"6","key":"5523_CR4","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00401-021-02299-y","volume":"141","author":"F Ingelfinger","year":"2021","unstructured":"Ingelfinger F, Krishnarajah S, Kramer M et al (2021) Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature. Acta Neuropathol 141(6):901\u2013915","journal-title":"Acta Neuropathol"},{"issue":"2","key":"5523_CR5","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000945","volume":"8","author":"S Ashida","year":"2021","unstructured":"Ashida S, Ochi H, Hamatani M, Fujii C, Kimura K, Okada Y, Hashi Y, Kawamura K, et al. (2021) Immune skew of circulating follicular helper T cells associates with myasthenia gravis severity. Neurol Neuroimmunol Neuroinflamm 8(2):e945. https:\/\/doi.org\/10.1212\/NXI.0000000000000945","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"10","key":"5523_CR6","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1182\/blood-2005-11-4502","volume":"107","author":"DM Zhao","year":"2006","unstructured":"Zhao DM, Thornton AM, DiPaolo RJ et al (2006) Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 107(10):3925\u20133932","journal-title":"Blood"},{"issue":"3","key":"5523_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40037-021-00695-4","volume":"11","author":"A Ninkov","year":"2022","unstructured":"Ninkov A, Frank JR, Maggio LA (2022) Bibliometrics: methods for studying academic publishing. Perspect Med Educ 11(3):173\u2013176. https:\/\/doi.org\/10.1007\/s40037-021-00695-4","journal-title":"Perspect Med Educ"},{"issue":"2","key":"5523_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"NJ van Eck","year":"2010","unstructured":"van Eck NJ, Waltman L (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84(2):523\u2013538","journal-title":"Scientometrics"},{"issue":"9","key":"5523_CR9","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1517\/14712598.2014.920813","volume":"14","author":"C Chen","year":"2014","unstructured":"Chen C, Dubin R, Kim MC (2014) Emerging trends and new developments in regenerative medicine: a scientometric update (2000 - 2014). Expert Opin Biol Ther 14(9):1295\u20131317. https:\/\/doi.org\/10.1517\/14712598.2014.920813","journal-title":"Expert Opin Biol Ther"},{"key":"5523_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.948314","volume":"13","author":"N Wei","year":"2022","unstructured":"Wei N, Xu Y, Li Y, Shi J, Zhang X, You Y, Sun Q, Zhai H, et al. (2022) A bibliometric analysis of T cell and atherosclerosis. Front Immunol 13:948314. https:\/\/doi.org\/10.3389\/fimmu.2022.948314","journal-title":"Front Immunol"},{"key":"5523_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2021.113932","volume":"201","author":"X Liu","year":"2022","unstructured":"Liu X, Zhao S, Tan L et al (2022) Frontier and hot topics in electrochemiluminescence sensing technology based on CiteSpace bibliometric analysis. Biosens Bioelectron 201:113932","journal-title":"Biosens Bioelectron"},{"issue":"1","key":"5523_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/nyas.13519","volume":"1412","author":"MA Cron","year":"2018","unstructured":"Cron MA, Maillard S, Villegas J, Truffault F, Sudres M, Dragin N, Berrih\u2010Aknin S, Le Panse R (2018) Thymus involvement in early-onset myasthenia gravis. Ann N Y Acad Sci 1412(1):137\u2013145. https:\/\/doi.org\/10.1111\/nyas.13519","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"5523_CR13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/nyas.13591","volume":"1413","author":"JA Villegas","year":"2018","unstructured":"Villegas JA, Van Wassenhove J, Le Panse R et al (2018) An imbalance between regulatory T cells and T helper 17 cells in acetylcholine receptor-positive myasthenia gravis patients. Ann N Y Acad Sci 1413(1):154\u2013162","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"5523_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM (2019) Myasthenia gravis. Nat Rev Dis Primers 5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"5523_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/mus.25973","volume":"57","author":"JS Yi","year":"2018","unstructured":"Yi JS, Guptill JT, Stathopoulos P, Nowak RJ, O\u2019Connor KC (2018) B cells in the pathophysiology of myasthenia gravis. Muscle Nerve 57(2):172\u2013184. https:\/\/doi.org\/10.1002\/mus.25973","journal-title":"Muscle Nerve"},{"issue":"3","key":"5523_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G et al (2021) International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 96(3):114\u2013122","journal-title":"Neurology"},{"issue":"7","key":"5523_CR17","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr","year":"2021","unstructured":"Howard JF Jr, Bril V, Vu T et al (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526\u2013536","journal-title":"Lancet Neurol"},{"key":"5523_CR18","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3389\/fimmu.2020.00809","volume":"11","author":"M \u00c7ebi","year":"2020","unstructured":"\u00c7ebi M, Durmus H, Aysal F et al (2020) CD4+ T cells of myasthenia gravis patients are characterized by increased IL-21, IL-4, and IL-17A productions and higher presence of PD-1 and ICOS. Front Immunol 11:809","journal-title":"Front Immunol"},{"issue":"2","key":"5523_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","volume":"15","author":"MC Dalakas","year":"2019","unstructured":"Dalakas MC (2019) Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol 15(2):113\u2013124","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"5523_CR20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/cei.13546","volume":"203","author":"A Uzawa","year":"2021","unstructured":"Uzawa A, Kuwabara S, Suzuki S et al (2021) Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol 203(3):366\u2013374","journal-title":"Clin Exp Immunol"},{"key":"5523_CR21","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","volume":"11","author":"K Lazaridis","year":"2020","unstructured":"Lazaridis K, Tzartos SJ (2020) Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics. Front Immunol 11:212","journal-title":"Front Immunol"},{"issue":"1","key":"5523_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/nyas.13560","volume":"1413","author":"M Sudres","year":"2018","unstructured":"Sudres M, Verdier J, Truffault F et al (2018) Pathophysiological mechanisms of autoimmunity. Ann N Y Acad Sci 1413(1):59\u201368","journal-title":"Ann N Y Acad Sci"},{"key":"5523_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00169","volume":"8","author":"A Lopomo","year":"2017","unstructured":"Lopomo A, Berrih-Aknin S (2017) Autoimmune thyroiditis and myasthenia gravis. Front Endocrinol (Lausanne) 8:169. https:\/\/doi.org\/10.3389\/fendo.2017.00169","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"5523_CR24","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1517\/14712598.5.7.983","volume":"5","author":"S Berrih-Aknin","year":"2005","unstructured":"Berrih-Aknin S, Fuchs S, Souroujon MC (2005) Vaccines against myasthenia gravis. Expert Opin Biol Ther 5(7):983\u2013995. https:\/\/doi.org\/10.1517\/14712598.5.7.983","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"5523_CR25","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.autrev.2011.01.005","volume":"10","author":"E Ben-Ami","year":"2011","unstructured":"Ben-Ami E, Berrih-Aknin S, Miller A (2011) Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev 10(7):410\u2013415","journal-title":"Autoimmun Rev"},{"issue":"5","key":"5523_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e26741","volume":"10","author":"J Dong","year":"2024","unstructured":"Dong J, Duan RS, Zhang P (2024) Causal relationship between the immune phenotype of monocytes and myasthenia gravis: a Mendelian randomization study. Heliyon 10(5):e26741. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26741","journal-title":"Heliyon"},{"key":"5523_CR27","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jconrel.2023.11.006","volume":"364","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Du T, Yang CL et al (2023) Extracellular vesicles encapsulated with caspase-1 inhibitor ameliorate experimental autoimmune myasthenia gravis through targeting macrophages. J Control Release 364:458\u2013472","journal-title":"J Control Release"},{"key":"5523_CR28","doi-asserted-by":"crossref","unstructured":"Wolfe GI, Kaminski HJ, Aban IB et al (2017) Randomized Trial of thymectomy in myasthenia gravis [published correction appears in. N Engl J Med 376(21):2097","DOI":"10.1056\/NEJMx170003"},{"key":"5523_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaut.2013.12.015","volume":"52","author":"A Gradolatto","year":"2014","unstructured":"Gradolatto A, Nazzal D, Truffault F, Bismuth J, Fadel E, Foti M, Berrih-Aknin S (2014) Both Treg cells and Tconv cells are defective in the myasthenia gravis thymus: roles of IL-17 and TNF-\u03b1. J Autoimmun 52:53\u201363. https:\/\/doi.org\/10.1016\/j.jaut.2013.12.015","journal-title":"J Autoimmun"},{"key":"5523_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","volume":"52","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin S, Le Panse R (2014) Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. J Autoimmun 52:90\u2013100. https:\/\/doi.org\/10.1016\/j.jaut.2013.12.011","journal-title":"J Autoimmun"},{"issue":"3","key":"5523_CR31","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/bja\/aer124","volume":"107","author":"IK Moppett","year":"2011","unstructured":"Moppett IK, Hardman JG (2011) Bibliometrics of anaesthesia researchers in the UK. Br J Anaesth 107(3):351\u2013356. https:\/\/doi.org\/10.1093\/bja\/aer124","journal-title":"Br J Anaesth"},{"issue":"1","key":"5523_CR32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12264-010-0604-1","volume":"26","author":"S Huang","year":"2010","unstructured":"Huang S, Tan LM (2010) Research advancement in immunopathogenesis of myasthenia gravis. Neurosci Bull 26(1):85\u201389","journal-title":"Neurosci Bull"},{"issue":"1","key":"5523_CR33","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12974-024-03095-7","volume":"21","author":"\u0130 Alt\u0131n\u00f6nder","year":"2024","unstructured":"Alt\u0131n\u00f6nder \u0130, Kaya M, Yent\u00fcr SP et al (2024) Thymic gene expression analysis reveals a potential link between HIF-1A and Th17\/Treg imbalance in thymoma associated myasthenia gravis. J Neuroinflammation 21(1):126","journal-title":"J Neuroinflammation"},{"issue":"2","key":"5523_CR34","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1093\/bjs\/znaa076","volume":"108","author":"R Zhang","year":"2021","unstructured":"Zhang R, Qi S, Dai W et al (2021) Publication trends and hotspots in enhanced recovery after surgery: 20-year bibliometric analysis. Br J Surg 108(2):e62\u2013e64","journal-title":"Br J Surg"},{"key":"5523_CR35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/B978-0-12-823912-4.00026-8","volume":"200","author":"MR Tannemaat","year":"2024","unstructured":"Tannemaat MR, Huijbers MG, Verschuuren JJGM (2024) Myasthenia gravis-pathophysiology, diagnosis, and treatment. Handb Clin Neurol 200:283\u2013305","journal-title":"Handb Clin Neurol"},{"key":"5523_CR36","doi-asserted-by":"publisher","first-page":"1404191","DOI":"10.3389\/fimmu.2024.1404191","volume":"15","author":"P Cavalcante","year":"2024","unstructured":"Cavalcante P, Mantegazza R, Antozzi C (2024) Targeting autoimmune mechanisms by precision medicine in myasthenia gravis. Front Immunol 15:1404191","journal-title":"Front Immunol"},{"key":"5523_CR37","first-page":"43","volume":"182","author":"AC Bayer","year":"2025","unstructured":"Bayer AC, Nowak RJ, O\u2019Connor KC (2025) Contribution of cellular immune dysregulation to myasthenia gravis pathology. Int Rev Neurobiol 182:43\u201366","journal-title":"Int Rev Neurobiol"},{"issue":"18","key":"5523_CR38","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3390\/cells13181550","volume":"13","author":"N Iacomino","year":"2024","unstructured":"Iacomino N, Tarasco MC, Berni A et al (2024) Non-coding RNAs in Myasthenia Gravis: from immune regulation to personalized medicine. Cells 13(18):1550","journal-title":"Cells"},{"key":"5523_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2023.578205","volume":"384","author":"M Yasuda","year":"2023","unstructured":"Yasuda M, Uzawa A, Ozawa Y, Kojima Y, Onishi Y, Akamine H, Kuwabara S (2023) Serum cytokine profiles in myasthenia gravis with anti-muscle-specific kinase antibodies. J Neuroimmunol 384:578205. https:\/\/doi.org\/10.1016\/j.jneuroim.2023.578205","journal-title":"J Neuroimmunol"},{"issue":"1","key":"5523_CR40","doi-asserted-by":"publisher","first-page":"1756130","DOI":"10.1080\/2162402X.2020.1756130","volume":"9","author":"J Thanner","year":"2020","unstructured":"Thanner J, Bekos C, Veraar C et al (2020) Heat shock protein 90\u03b1 in thymic epithelial tumors and non-thymomatous myasthenia gravis. Oncoimmunology 9(1):1756130","journal-title":"Oncoimmunology"},{"issue":"8","key":"5523_CR41","doi-asserted-by":"publisher","first-page":"5100","DOI":"10.4049\/jimmunol.176.8.5100","volume":"176","author":"Y Matsumoto","year":"2006","unstructured":"Matsumoto Y, Matsuo H, Sakuma H et al (2006) CDR3 spectratyping analysis of the TCR repertoire in myasthenia gravis. J Immunol 176(8):5100\u20135107","journal-title":"J Immunol"},{"key":"5523_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577279","volume":"345","author":"Y Li","year":"2020","unstructured":"Li Y, Guptill JT, Russo MA et al (2020) Imbalance in T follicular helper cells producing IL-17 promotes pro-inflammatory responses in MuSK antibody positive myasthenia gravis. J Neuroimmunol 345:577279","journal-title":"J Neuroimmunol"},{"issue":"4","key":"5523_CR43","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1365-3083.1995.tb03680.x","volume":"42","author":"GX Zhang","year":"1995","unstructured":"Zhang GX, Ma CG, Xiao BG, Bakhiet M, Ljungdahl A, Olsson T, Link H (1995) Suppression of experimental autoimmune myasthenia gravis after CD8 depletion is associated with decreased IFN-gamma and IL-4. Scand J Immunol 42(4):457\u2013465. https:\/\/doi.org\/10.1111\/j.1365-3083.1995.tb03680.x","journal-title":"Scand J Immunol"},{"issue":"9","key":"5523_CR44","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.4049\/jimmunol.174.9.5324","volume":"174","author":"T Feferman","year":"2005","unstructured":"Feferman T, Maiti PK, Berrih-Aknin S, Bismuth J, Bidault J, Fuchs S, Souroujon MC (2005) Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis. J Immunol 174(9):5324\u20135331. https:\/\/doi.org\/10.4049\/jimmunol.174.9.5324","journal-title":"J Immunol"},{"issue":"11","key":"5523_CR45","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/ni1254","volume":"6","author":"LE Harrington","year":"2005","unstructured":"Harrington LE, Hatton RD, Mangan PR et al (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6(11):1123\u20131132","journal-title":"Nat Immunol"},{"key":"5523_CR46","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1146\/annurev-immunol-103019-085803","volume":"38","author":"M Ruterbusch","year":"2020","unstructured":"Ruterbusch M, Pruner KB, Shehata L et al (2020) In vivo CD4+ T cell differentiation and function: revisiting the Th1\/Th2 paradigm. Annu Rev Immunol 38:705\u2013725","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"5523_CR47","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nri2295","volume":"8","author":"C Dong","year":"2008","unstructured":"Dong C (2008) TH17 cells in development: an updated view of their molecular identity and genetic programming. Nat Rev Immunol 8(5):337\u2013348","journal-title":"Nat Rev Immunol"},{"key":"5523_CR48","doi-asserted-by":"publisher","first-page":"1280029","DOI":"10.3389\/fimmu.2024.1280029","volume":"15","author":"X Song","year":"2024","unstructured":"Song X, He Y, Huo Y et al (2024) Normalized circulating Tfh and Th17 associates with improvement in myasthenia gravis treated with ofatumumab. Front Immunol 15:1280029","journal-title":"Front Immunol"},{"issue":"1-3","key":"5523_CR49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ejphar.2009.10.040","volume":"627","author":"M Masuda","year":"2010","unstructured":"Masuda M, Tanaka S, Nakajima K et al (2010) Clinical implications of the type 1\/type 2 balance of helper T cells and P-glycoprotein function in peripheral T lymphocytes of myasthenia gravis patients. Eur J Pharmacol 627(1\u20133):325\u2013331","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"5523_CR50","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/imm.12322","volume":"143","author":"X Yao","year":"2014","unstructured":"Yao X, Kong Q, Xie X et al (2014) Neutralization of interleukin-9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses. Immunology 143(3):396\u2013405","journal-title":"Immunology"},{"issue":"1","key":"5523_CR51","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/638968","volume":"2015","author":"X Fan","year":"2015","unstructured":"Fan X, Lin C, Han J, Jiang X, Zhu J, Jin T (2015) Follicular helper CD4+ T cells in human neuroautoimmune diseases and their animal models. Mediators Inflamm 2015(1):638968. https:\/\/doi.org\/10.1155\/2015\/638968","journal-title":"Mediators Inflamm"},{"issue":"1","key":"5523_CR52","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s12035-014-8985-1","volume":"53","author":"X Zhang","year":"2016","unstructured":"Zhang X, Liu S, Chang T et al (2016) Intrathymic Tfh\/B cells interaction leads to ectopic GCs formation and anti-AChR antibody production: central role in triggering MG occurrence. Mol Neurobiol 53(1):120\u2013131","journal-title":"Mol Neurobiol"},{"key":"5523_CR53","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.neulet.2016.07.049","volume":"630","author":"Y Wen","year":"2016","unstructured":"Wen Y, Yang B, Lu J, Zhang J, Yang H, Li J (2016) Imbalance of circulating CD4(+)CXCR5(+)FOXP3(+) Tfr-like cells and CD4(+)CXCR5(+)FOXP3(-) Tfh-like cells in myasthenia gravis. Neurosci Lett 630:176\u2013182. https:\/\/doi.org\/10.1016\/j.neulet.2016.07.049","journal-title":"Neurosci Lett"},{"issue":"7","key":"5523_CR54","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.4049\/jimmunol.1500725","volume":"197","author":"CJ Zhang","year":"2016","unstructured":"Zhang CJ, Gong Y, Zhu W et al (2016) Augmentation of circulating follicular helper T cells and their impact on autoreactive B cells in myasthenia gravis. J Immunol 197(7):2610\u20132617","journal-title":"J Immunol"},{"issue":"5","key":"5523_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1450","volume":"12","author":"MR Ge","year":"2023","unstructured":"Ge MR, Yang CL, Li T et al (2023) Circulating CXCR5+ natural killer cells are expanded in patients with myasthenia gravis. Clin Transl Immunol 12(5):e1450","journal-title":"Clin Transl Immunol"},{"issue":"10","key":"5523_CR56","doi-asserted-by":"publisher","first-page":"739","DOI":"10.2174\/1566524019666190827162615","volume":"19","author":"L Wang","year":"2019","unstructured":"Wang L, Zhang Y, Zhu M, Feng J, Han J, Zhu J, Deng H (2019) Effects of follicular helper T cells and inflammatory cytokines on myasthenia gravis. Curr Mol Med 19(10):739\u2013745. https:\/\/doi.org\/10.2174\/1566524019666190827162615","journal-title":"Curr Mol Med"},{"issue":"3","key":"5523_CR57","first-page":"257","volume":"38","author":"L Ma","year":"2022","unstructured":"Ma L, Wu T, He J et al (2022) Detection of memory T cells, follicular T cells and relevant cytokines in the peripheral blood of patients with myasthenia gravis during treatment. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 38(3):257\u2013262","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"issue":"1","key":"5523_CR58","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41421-021-00314-w","volume":"7","author":"W Jin","year":"2021","unstructured":"Jin W, Yang Q, Peng Y et al (2021) Single-cell RNA-Seq reveals transcriptional heterogeneity and immune subtypes associated with disease activity in human myasthenia gravis. Cell Discov 7(1):85","journal-title":"Cell Discov"},{"key":"5523_CR59","doi-asserted-by":"publisher","first-page":"1108116","DOI":"10.3389\/fimmu.2023.1108116","volume":"14","author":"L M\u00fcller-Jensen","year":"2023","unstructured":"M\u00fcller-Jensen L, Knauss S, Ginesta Roque L et al (2023) Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events. Front Immunol 14:1108116","journal-title":"Front Immunol"},{"issue":"2","key":"5523_CR60","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2003-11-3900","volume":"105","author":"A Balandina","year":"2005","unstructured":"Balandina A, L\u00e9cart S, Dartevelle P et al (2005) Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 105(2):735\u2013741","journal-title":"Blood"},{"issue":"11","key":"5523_CR61","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.it.2016.08.012","volume":"37","author":"M Kanamori","year":"2016","unstructured":"Kanamori M, Nakatsukasa H, Okada M, Lu Q, Yoshimura A (2016) Induced regulatory T cells: their development, stability, and applications. Trends Immunol 37(11):803\u2013811. https:\/\/doi.org\/10.1016\/j.it.2016.08.012","journal-title":"Trends Immunol"},{"issue":"6","key":"5523_CR62","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nri3464","volume":"13","author":"S Sakaguchi","year":"2013","unstructured":"Sakaguchi S, Vignali D, Rudensky A, Vignali DAA, Rudensky AY, Niec RE, Waldmann H (2013) The plasticity and stability of regulatory T cells. Nat Rev Immunol 13(6):461\u2013467. https:\/\/doi.org\/10.1038\/nri3464","journal-title":"Nat Rev Immunol"},{"issue":"26","key":"5523_CR63","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375(26):2570\u20132581. https:\/\/doi.org\/10.1056\/NEJMra1602678","journal-title":"N Engl J Med"},{"issue":"3","key":"5523_CR64","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/jnc.16047","volume":"168","author":"X Huang","year":"2024","unstructured":"Huang X, An X, Gao X, Wang N, Liu J, Zhang Y, Qi G, Zhang C (2024) Serum amyloid A facilitates expansion of CD4+ T cell and CD19+ B cell subsets implicated in the severity of myasthenia gravis patients. J Neurochem 168(3):224\u2013237. https:\/\/doi.org\/10.1111\/jnc.16047","journal-title":"J Neurochem"},{"key":"5523_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.686466","volume":"12","author":"C Zografou","year":"2021","unstructured":"Zografou C, Vakrakou AG, Stathopoulos P (2021) Short- and long-lived autoantibody-secreting cells in autoimmune neurological disorders. Front Immunol 12:686466. https:\/\/doi.org\/10.3389\/fimmu.2021.686466","journal-title":"Front Immunol"},{"key":"5523_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1382320","volume":"15","author":"Y Okuzono","year":"2024","unstructured":"Okuzono Y, Miyakawa S, Itou T et al (2024) B-cell immune dysregulation with low soluble CD22 levels in refractory seronegative myasthenia gravis. Front Immunol 15:1382320","journal-title":"Front Immunol"},{"issue":"6","key":"5523_CR67","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/mus.24063","volume":"48","author":"JS Yi","year":"2013","unstructured":"Yi JS, Decroos EC, Sanders DB, Weinhold KJ, Guptill JT (2013) Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment. Muscle Nerve 48(6):992\u2013993. https:\/\/doi.org\/10.1002\/mus.24063","journal-title":"Muscle Nerve"},{"issue":"2","key":"5523_CR68","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/mus.25597","volume":"56","author":"R Tandan","year":"2017","unstructured":"Tandan R, Hehir MK, Waheed W, Howard DB (2017) Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve 56(2):185\u2013196. https:\/\/doi.org\/10.1002\/mus.25597","journal-title":"Muscle Nerve"},{"key":"5523_CR69","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jneuroim.2016.05.004","volume":"297","author":"JR Sheng","year":"2016","unstructured":"Sheng JR, Rezania K, Soliven B (2016) Impaired regulatory B cells in myasthenia gravis. J Neuroimmunol 297:38\u201345. https:\/\/doi.org\/10.1016\/j.jneuroim.2016.05.004","journal-title":"J Neuroimmunol"},{"issue":"1","key":"5523_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-024-00401-y","volume":"64","author":"GM Tavakoli","year":"2024","unstructured":"Tavakoli GM, Yazdanpanah N, Rezaei N (2024) Targeting Bruton\u2019s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments. Adv Rheumatol 64(1):61","journal-title":"Adv Rheumatol"},{"key":"5523_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2021.128229","volume":"48","author":"J Zheng","year":"2021","unstructured":"Zheng J, Chen D, Xu J et al (2021) Small molecule approaches to treat autoimmune and inflammatory diseases (Part III): targeting cytokines and cytokine receptor complexes. Bioorg Med Chem Lett 48:128229","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"5523_CR72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12865-022-00501-8","volume":"23","author":"X Huan","year":"2022","unstructured":"Huan X, Zhao R, Song J et al (2022) Increased serum IL-2, IL-4, IL-5 and IL-12p70 levels in AChR subtype generalized myasthenia gravis. BMC Immunol 23(1):26","journal-title":"BMC Immunol"},{"issue":"1","key":"5523_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53250-6","volume":"14","author":"P Zhang","year":"2024","unstructured":"Zhang P, Liu YX, Chen S et al (2024) Distribution of multi-level B cell subsets in thymoma and thymoma-associated myasthenia gravis. Sci Rep 14(1):2674","journal-title":"Sci Rep"},{"issue":"4","key":"5523_CR74","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3390\/cells11040740","volume":"11","author":"F Beretta","year":"2022","unstructured":"Beretta F, Huang YF, Punga AR (2022) Towards personalized medicine in myasthenia gravis: role of circulating microRNAs miR-30e-5p, miR-150-5p and miR-21-5p. Cells 11(4):740","journal-title":"Cells"},{"issue":"6","key":"5523_CR75","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41419-019-1667-1","volume":"10","author":"Z Wang","year":"2019","unstructured":"Wang Z, Zhu H, Shi H et al (2019) Exosomes derived from M1 macrophages aggravate neointimal hyperplasia following carotid artery injuries in mice through miR-222\/CDKN1B\/CDKN1C pathway. Cell Death Dis 10(6):422","journal-title":"Cell Death Dis"},{"issue":"B","key":"5523_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108223","volume":"101","author":"M Zhou","year":"2021","unstructured":"Zhou M, Li B, Liu C et al (2021) M2 macrophage-derived exosomal miR-501 contributes to pubococcygeal muscle regeneration. Int Immunopharmacol 101(B):108223","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"5523_CR77","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","volume":"22","author":"V Bril","year":"2023","unstructured":"Bril V, Dru\u017cd\u017c A, Grosskreutz J et al (2023) Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol 22(5):383\u2013394","journal-title":"Lancet Neurol"},{"issue":"10","key":"5523_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102366","volume":"18","author":"AW Zuercher","year":"2019","unstructured":"Zuercher AW, Spirig R, Baz Morelli A, Rowe T, K\u00e4sermann F (2019) Next-generation Fc receptor-targeting biologics for autoimmune diseases. Autoimmun Rev 18(10):102366. https:\/\/doi.org\/10.1016\/j.autrev.2019.102366","journal-title":"Autoimmun Rev"},{"issue":"3","key":"5523_CR79","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1136\/annrheumdis-2021-220066","volume":"81","author":"Y Wang","year":"2022","unstructured":"Wang Y, Xie X, Zhang C et al (2022) Rheumatoid arthritis, systemic lupus erythematosus and primary Sj\u00f6gren\u2019s syndrome shared megakaryocyte expansion in peripheral blood. Ann Rheum Dis 81(3):379\u2013385","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"5523_CR80","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41584-022-00841-0","volume":"18","author":"A Tison","year":"2022","unstructured":"Tison A, Garaud S, Chiche L et al (2022) Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. Nat Rev Rheumatol 18(11):641\u2013656","journal-title":"Nat Rev Rheumatol"},{"key":"5523_CR81","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.semcancer.2019.06.012","volume":"64","author":"S Khan","year":"2020","unstructured":"Khan S, Gerber DE (2020) Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin Cancer Biol 64:93\u2013101. https:\/\/doi.org\/10.1016\/j.semcancer.2019.06.012","journal-title":"Semin Cancer Biol"},{"key":"5523_CR82","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","volume":"19","author":"AM Haugh","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB (2020) Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf 19:479\u2013488","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"5523_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","volume":"7","author":"H Safa","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA et al (2019) Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer 7(1):319","journal-title":"J Immunother Cancer"},{"issue":"17","key":"5523_CR84","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36(17):1714\u201368","journal-title":"J Clin Oncol"},{"issue":"6","key":"5523_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006814","volume":"11","author":"F Fa'ak","year":"2023","unstructured":"Fa\u2019ak F, Buni M, Falohun A, Lu H, Song J, Johnson DH, Zobniw CM, Trinh VA, et al. (2023) Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. J Immunother Cancer 11(6):e006814. https:\/\/doi.org\/10.1136\/jitc-2023-006814","journal-title":"J Immunother Cancer"},{"key":"5523_CR86","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jns.2017.05.060","volume":"379","author":"SW Ahn","year":"2017","unstructured":"Ahn SW, Joo IS, Kim BJ et al (2017) A multicenter prospective observational study on the safety and efficacy of tacrolimus in patients with myasthenia gravis. J Neurol Sci 379:271\u2013275","journal-title":"J Neurol Sci"},{"issue":"5","key":"5523_CR87","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1159\/000510396","volume":"83","author":"H Wu","year":"2020","unstructured":"Wu H, Wang Z, Xi J et al (2020) Therapeutic and immunoregulatory effects of tacrolimus in patients with refractory generalized myasthenia gravis. Eur Neurol 83(5):500\u2013507","journal-title":"Eur Neurol"},{"issue":"12","key":"5523_CR88","doi-asserted-by":"publisher","first-page":"3854","DOI":"10.1111\/ene.15872","volume":"30","author":"F Sacc\u00e0","year":"2023","unstructured":"Sacc\u00e0 F, Pane C, Espinosa PE et al (2023) Efficacy of innovative therapies in myasthenia gravis: a systematic review, meta-analysis and network meta-analysis. Eur J Neurol 30(12):3854\u20133867","journal-title":"Eur J Neurol"},{"issue":"9","key":"5523_CR89","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","volume":"41","author":"S Oh","year":"2023","unstructured":"Oh S, Mao X, Manfredo-Vieira S et al (2023) Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat Biotechnol 41(9):1229\u20131238","journal-title":"Nat Biotechnol"},{"issue":"11","key":"5523_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101794","volume":"5","author":"J Wickel","year":"2024","unstructured":"Wickel J, Schnetzke U, Sayer-Klink A et al (2024) Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome. Cell Rep Med. 5(11):101794","journal-title":"Cell Rep Med."},{"issue":"6","key":"5523_CR91","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315990121","volume":"121","author":"C Qin","year":"2024","unstructured":"Qin C, Dong MH, Zhou LQ, Wang W et al (2024) Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy. Proc Natl Acad Sci U S A 121(6):e2315990121","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"5523_CR92","doi-asserted-by":"publisher","first-page":"4655","DOI":"10.1007\/s00415-024-12367-4","volume":"271","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Liu D, Zhang Z, Huang X, Cao J, Wang G, Du X, Wang Z, et al. (2024) Bispecific BCMA\/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report. J Neurol 271(7):4655\u20134659. https:\/\/doi.org\/10.1007\/s00415-024-12367-4","journal-title":"J Neurol"},{"issue":"7","key":"5523_CR93","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit V, Benatar M, Kurtoglu M et al (2023) Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol 22(7):578\u2013590","journal-title":"Lancet Neurol"},{"issue":"5","key":"5523_CR94","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12071","volume":"10","author":"MI Zonneveld","year":"2021","unstructured":"Zonneveld MI, van Herwijnen MJC, Fernandez-Gutierrez MM et al (2021) Human milk extracellular vesicles target nodes in interconnected signalling pathways that enhance oral epithelial barrier function and dampen immune responses. J Extracell Vesicles 10(5):e12071","journal-title":"J Extracell Vesicles"},{"key":"5523_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2022.120268","volume":"437","author":"D Gelinas","year":"2022","unstructured":"Gelinas D, Parvin-Nejad S, Phillips G et al (2022) The humanistic burden of myasthenia gravis: a systematic literature review. J Neurol Sci 437:120268","journal-title":"J Neurol Sci"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05523-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05523-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05523-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T20:02:48Z","timestamp":1770321768000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05523-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["5523"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05523-y","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"419"}}